Home Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
Article
Licensed
Unlicensed Requires Authentication

Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review

  • Stefano Zoccolella , Giovanni Iliceto , Michele deMari , Paolo Livrea and Paolo Lamberti
Published/Copyright: December 8, 2007
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 12

Abstract

In recent years, L-Dopa treatment has been indicated as an acquired cause of hyperhomocysteinemia (HHcy). The mechanism underlying L-Dopa-related HHcy is the O-methylation of the drug catalyzed by the enzyme catechol-O-methyltransferase (COMT). Folate and cobalamin status also influences the effects of L-Dopa on plasma homocysteine (Hcy) levels. Although clinical correlations of HHcy in Parkinson's disease still remain uncertain, management of elevated plasma Hcy levels has been advocated, due to multiple cytotoxic effects of Hcy on neurons. This review summarizes data available in the literature concerning the two main therapeutic approaches to L-Dopa-related HHcy (use of COMT inhibitors or B vitamins diet supplementation).

Clin Chem Lab Med 2007;45:1607–13.

Keywords: cobalamin; entacapone; folate; homocysteine; L-Dopa; Parkinson's disease; tolcapone
Corresponding author: Prof Paolo Lamberti, Department of Neurological Sciences, University of Bari, Ospedale Policlinico, P.zza G. Cesare 11, 70124 Bari, Italy Phone: +39-080-5592321, Fax: +39-080-5478532,
Received: 2007-6-29
Accepted: 2007-8-14
Published Online: 2007-12-08
Published in Print: 2007-12-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Homocysteine research: alive and kicking!
  2. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis
  3. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial
  4. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients
  5. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases
  6. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
  7. Biomarkers of folate and vitamin B12 status in cerebrospinal fluid
  8. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis – a systematic review
  9. Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review
  10. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?
  11. Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
  12. Hyperhomocysteinemia, DNA methylation and vascular disease
  13. Measuring subclinical atherosclerosis: is homocysteine relevant?
  14. Plasma protein homocysteinylation in uremia
  15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease
  16. Hyperhomocysteinemia – association with renal transsulfuration and redox signaling in rats
  17. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine
  18. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias
  19. The molecular basis of homocysteine thiolactone-mediated vascular disease
  20. Importance of folate-homocysteine homeostasis during early embryonic development
  21. Association between homocysteine, vitamin B6 concentrations and inflammation
  22. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry
  23. Holotranscobalamin in laboratory diagnosis of cobalamin deficiency compared to total cobalamin and methylmalonic acid
  24. Haptocorrin in humans
  25. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase
  26. Decreased p66Shc promoter methylation in patients with end-stage renal disease
  27. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling
  28. Differential expression of γ-aminobutyric acid receptor A (GABAA) and effects of homocysteine
  29. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
  30. Acknowledgement
  31. Contents, Volume 45, 2007
  32. Author Index
  33. Subject Index
https://doi.org/10.1515/CCLM.2007.337
Keywords for this article
cobalamin; entacapone; folate; homocysteine; L-Dopa; Parkinson's disease; tolcapone

Articles in the same Issue

  1. Homocysteine research: alive and kicking!
  2. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis
  3. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial
  4. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients
  5. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases
  6. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
  7. Biomarkers of folate and vitamin B12 status in cerebrospinal fluid
  8. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis – a systematic review
  9. Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review
  10. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?
  11. Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
  12. Hyperhomocysteinemia, DNA methylation and vascular disease
  13. Measuring subclinical atherosclerosis: is homocysteine relevant?
  14. Plasma protein homocysteinylation in uremia
  15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease
  16. Hyperhomocysteinemia – association with renal transsulfuration and redox signaling in rats
  17. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine
  18. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias
  19. The molecular basis of homocysteine thiolactone-mediated vascular disease
  20. Importance of folate-homocysteine homeostasis during early embryonic development
  21. Association between homocysteine, vitamin B6 concentrations and inflammation
  22. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry
  23. Holotranscobalamin in laboratory diagnosis of cobalamin deficiency compared to total cobalamin and methylmalonic acid
  24. Haptocorrin in humans
  25. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase
  26. Decreased p66Shc promoter methylation in patients with end-stage renal disease
  27. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling
  28. Differential expression of γ-aminobutyric acid receptor A (GABAA) and effects of homocysteine
  29. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
  30. Acknowledgement
  31. Contents, Volume 45, 2007
  32. Author Index
  33. Subject Index
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 6.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.337/html?lang=en
Scroll to top button